Journal of Cancer Research and Therapeutics Close
 

Figure 3: Survival curves for the in vivo treatment study with NUGC4 cells stably expressing red fluorescent protein peritoneal disseminated mice. Kaplan–Meier survival curve for control (blue line), 64Cu-labeled cetuximab only (purple dotted line), vorinostat only (green dashed line), and 64Cu-labeled cetuximab + vorinostat (red dashed line) groups (n = 7/group). a, b, c: Different letters indicate significant difference (P < 0.05)

Figure 3: Survival curves for the in vivo treatment study with NUGC4 cells stably expressing red fluorescent protein peritoneal disseminated mice. Kaplan–Meier survival curve for control (blue line), <sup>64</sup>Cu-labeled cetuximab only (purple dotted line), vorinostat only (green dashed line), and <sup>64</sup>Cu-labeled cetuximab + vorinostat (red dashed line) groups (<i>n</i> = 7/group). a, b, c: Different letters indicate significant difference (<i>P</i> < 0.05)